

Acetic acid-promoted, efficient, one-pot synthesis of 2,3-dihydroquinazolin-4(1*H*)-ones

Zahed Karimi-Jaberi · Reza Arjmandi

Received: 30 September 2010 / Accepted: 30 March 2011 / Published online: 21 April 2011
© Springer-Verlag 2011

Abstract A simple, efficient, and general method has been developed for one-pot, three-component synthesis of 2,3-dihydroquinazolin-4(1*H*)-one derivatives based on a condensation reaction strategy of isatoic anhydride, aldehydes, and amines using acetic acid under reflux conditions.

Keywords 2,3-Dihydroquinazolin-4(1*H*)-ones · Isatoic anhydride · Acetic acid · Aldehydes · Amines

Introduction

In the mainstream of current interest, multicomponent reactions (MCRs) have been proven to be a very elegant and rapid way to access complex structures in a single synthetic operation from simple building blocks, showing high atom economy and high selectivity [1–3].


2,3-Dihydroquinazolines are an important class of heterocycles with a wide range of pharmacological and biological activities [4, 5]. Additionally, these compounds can easily be oxidized to their quinazolin-4(3*H*)-one analogs, which are themselves important biologically active compounds [6, 7]. Thus, efficient synthesis of these compounds has been of great interest in recent years. A number of synthetic methods for 2,3-dihydroquinazolin-4(1*H*)-ones have been developed during the past two decades [8–10]. One-pot three-component condensation of isatoic anhydride, aldehydes, and amines is the most convenient method for preparation of these compounds. In this

context, some methods and catalysts have been reported [11–22]. Developing versatile approaches towards synthesis of 2,3-dihydroquinazolin-4(1*H*)-ones still remains a highly desired goal in organic synthesis.

In view of our ongoing efforts to explore newer reactions for synthesis of heterocyclic compounds [23–25], we decided to investigate the possibility of synthesizing 2,3-dihydroquinazolin-4(1*H*)-one derivatives based on a one-pot three-component condensation reaction strategy of isatoic anhydride, aldehydes, and amines using acetic acid (Scheme 1).

Results and discussion

To optimize the reaction conditions, the reaction between benzaldehyde, aniline, and isatoic anhydride was used as a model reaction. The optimized reactant ratios were found to be 1.0 equiv. benzaldehyde, 1.1 equiv. aniline, and 1.0 equiv. isatoic anhydride in the presence of 5 cm³ acetic acid. The expected 2,3-diphenylquinazolin-4(1*H*)-one was produced in 79% yield after 2.5 h under reflux in acetic acid. To establish the generality and scope of the acetic acid-promoted 2,3-dihydroquinazolin-4(1*H*)-one synthesis, the reaction was examined with various structurally diverse aldehydes, amines, and isatoic anhydride. The results are summarized in Table 1. The structure of the products was



Scheme 1

Z. Karimi-Jaberi (✉) · R. Arjmandi
Department of Chemistry, Islamic Azad University,
Firoozabad Branch, P.O. Box 74715-117,
Firoozabad, Fars, Iran
e-mail: zahed.karimi@yahoo.com

Table 1 Synthesis of 2,3-dihydroquinazolin-4(1*H*)-ones


Comp.	R ¹	R ²	Time (h)	Yield (%)	M.p. (°C)	Ref.
1	Ph	Ph	2.5	79	209–211	[11]
2	3-O ₂ NC ₆ H ₄	Ph	1.5	92	186–188	[11]
3	4-O ₂ NC ₆ H ₄	Ph	1.5	92	195–197	[11]
4	2-O ₂ NC ₆ H ₄	Ph	1.5	91	179–181	[22]
5	4-ClC ₆ H ₄	Ph	2	89	226–228	[11]
6	2-ClC ₆ H ₄	Ph	2	93	136–138	[22]
7	2,6-Cl ₂ C ₆ H ₃	Ph	1.5	93	234–236	–
8	2,4-Cl ₂ C ₆ H ₃	Ph	1.5	91	189–191	–
9	2-Cl-6-FC ₆ H ₃	Ph	1.5	82	208–210	–
10	Ph	PhCH ₂	1	85	160–162	[11]
11	3-O ₂ NC ₆ H ₄	PhCH ₂	2	88	153–155	–
12	2-O ₂ NC ₆ H ₄	PhCH ₂	1	85	133–135	–
13	2-ClC ₆ H ₄	PhCH ₂	1.5	88	174–176	–
14	2,3-Cl ₂ C ₆ H ₃	PhCH ₂	1.5	88	206–208	–
15	2-Cl-6-FC ₆ H ₃	PhCH ₂	1	86	213–215	–
16	Ph	2-ClC ₆ H ₄ CH ₂	2	91	175–177	–
17	3-O ₂ NC ₆ H ₄	2-ClC ₆ H ₄ CH ₂	2.5	89	174–176	–
18	4-O ₂ NC ₆ H ₄	2-ClC ₆ H ₄ CH ₂	1	90	205–207	–
19	2-ClC ₆ H ₄	2-ClPhCH ₂	1	93	174–176	–
20	2,6-Cl ₂ C ₆ H ₃	2-ClC ₆ H ₄ CH ₂	1	91	184–186	–
21	2,4-Cl ₂ C ₆ H ₃	2-ClC ₆ H ₄ CH ₂	1	97	141–143	–
22	2-Cl-6-FC ₆ H ₃	2-ClC ₆ H ₄ CH ₂	1	82	203–205	–

deduced from their infrared (IR), ¹H nuclear magnetic resonance (NMR), ¹³C NMR, and elemental analysis.

The reaction can also proceed with several functionalities present on the aromatic amine, such as halogen and nitro groups. The reaction has also been done with various benzyl amines. In all these cases, the corresponding 2,3-dihydroquinazolines were obtained in good yields. It is important to note that, in the absence of acetic acid, the reaction yield was too low even at 120 °C after 5 h.

The mechanism of this reaction is believed to proceed through condensation of isatoic anhydride with amine followed by decarboxylation to yield the corresponding 2-aminobenzamide. Condensation of the aldehyde with the amino group of 2-aminobenzamide then gives an imine which undergoes cyclization to afford the 2,3-dihydroquinazoline product as shown in Scheme 2 [11].

To show the merit of the present work in comparison with results reported in the literature, we compared results of acetic acid with montmorillonite K-10 [12], silica sulfuric acid [14], KAl(SO₄)₂·12H₂O (alum) [11], Zn(PFO)₂ [16], Ga(OTf)₃ [13], and copolymer-PTSA (para-toluene-sulfonic acid) [18] as catalysts in the reaction of isatoic anhydride, aniline, and benzaldehyde in the synthesis of 2,3-dihydro-2-phenylquinazolin-4(1*H*)-one. As shown in Table 2, acetic acid can act as an effective catalyst with

**Scheme 2**

respect to reaction times and yields of the obtained products. Thus, the present protocol with acetic acid as a catalyst is an alternate route for production of 2,3-dihydroquinazolin-4(1*H*)-ones.

In conclusion, this paper describes a convenient and efficient process for synthesis of 2,3-dihydroquinazolin-4(1*H*)-ones by one-pot reaction of isatoic anhydride, aldehydes, and amines using acetic acid under reflux conditions. Several derivatives of the title compounds with different substituents were synthesized to show the diversity of the method. The method offers several advantages, such as the lack of any toxic solvent or catalyst, simplicity of performance, low cost, and improved yields. Starting materials are inexpensive and commercially available.

Experimental

Products were characterized by comparison of their physical and spectral data with those of authentic samples. All yields refer to isolated products after recrystallization. IR and NMR spectra were recorded on PerkinElmer 781 and Bruker DPX400 machines. The progress of the reactions was monitored by thin-layer chromatography (TLC).

General procedure for preparation of 2,3-dihydroquinazolin-4(1*H*)-ones

A mixture of aldehyde (1 mmol), amine (1.1 mmol), and isatoic anhydride (1 mmol) in 5 cm³ acetic acid was stirred under reflux for the appropriate time indicated in Table 1. After completion of the reaction, as indicated by TLC (ethyl acetate/*n*-hexane, 1/2), the reaction mixture was poured into 20 cm³ ice water. On solidification, it was filtered, washed with ice water, and recrystallized from ethanol to give the pure 2,3-dihydroquinazolin-4(1*H*)-ones.

2-(2,6-Dichlorophenyl)-2,3-dihydro-3-phenylquinazolin-4(1*H*)-one (7, C₂₀H₁₄Cl₂N₂O)

¹H NMR (CDCl₃): δ = 4.43 (br, 1H, NH), 6.65 (d, *J* = 8.0 Hz, 1H, CH), 6.88–6.92 (m, 1H, Ar-H), 7.09–7.27 (m, 6H, Ar-H), 7.29–7.43 (m, 4H, Ar-H), 8.02–8.05 (m, 1H, Ar-H) ppm; ¹³C NMR (CDCl₃): δ = 70.68, 114.05,

Table 2 Comparison of efficiency of various catalysts in the reaction of isatoic anhydride, aniline, and benzaldehyde

Entry	Catalyst	Conditions	Time (h)	Yield (%)	Ref.
1	Montmorillonite K-10 (0.3 g)	EtOH, reflux	6.5	80	[12]
2	Silica sulfuric acid, 20 mol% (0.06 g)	Solvent-free, 80 °C	5	80	[14]
3	KAl(SO ₄) ₂ ·12H ₂ O (alum, 0.2 g)	EtOH, reflux	4	78	[11]
4	[Zn(PFO) ₂] (0.027 g, 0.03 mmol)	H ₂ O/EtOH (1/3), reflux	6	82	[16]
5	Ga(OTf) ₃ (1 mol%)	EtOH, reflux	1	79	[13]
6	Copolymer-PTSA (0.3 g)	EtOH, reflux	6.5	82	[18]
7	Acetic acid	Reflux	2.5	79	–

115.03, 118.95, 127.30, 127.53, 128.66, 129.00, 129.56, 130.51, 132.53, 133.92, 135.99, 138.69, 145.79, 163.24 ppm.

2-(2,4-Dichlorophenyl)-2,3-dihydro-3-phenylquinazolin-4(1H)-one (8, C₂₀H₁₄Cl₂N₂O)

¹H NMR (CDCl₃): δ = 5.21 (br, 1H, NH), 6.42 (s, 1H, CH), 6.62 (d, J = 8.0 Hz, 1H, Ar-H), 6.89–6.94 (m, 1H, Ar-H), 7.21–7.29 (m, 3H, Ar-H), 7.31–7.40 (m, 3H, Ar-H), 7.40–7.43 (m, 1H, Ar-H), 7.52–7.55 (m, 1H, Ar-H), 7.90 (d, J = 8.0 Hz, 1H, Ar-H), 8.05 (d, J = 1.2 Hz, 1H, Ar-H) ppm; ¹³C NMR (CDCl₃): δ = 70.76, 114.95, 116.56, 119.90, 125.71, 126.89, 127.59, 129.06, 129.11, 130.17, 132.19, 134.19, 135.41, 135.48, 140.57, 144.46, 163.10 ppm.

2-(2-Chloro-6-fluorophenyl)-2,3-dihydro-3-phenylquinazolin-4(1H)-one (9, C₂₀H₁₄ClF₂N₂O)

¹H NMR (CDCl₃): δ = 4.65 (br, 1H, NH), 6.67 (d, J = 8.0 Hz, 1H, CH), 6.91–6.96 (m, 2H, Ar-H), 7.11–7.14 (m, 1H, Ar-H), 7.17–7.25 (m, 3H, Ar-H), 7.28 (d, J = 2.8 Hz, 2H, Ar-H), 7.29 (d, J = 3.6 Hz, 2H, Ar-H), 7.31–7.37 (m, 1H, Ar-H), 8.05–8.08 (m, 1H, Ar-H) ppm; ¹³C NMR (CDCl₃): δ = 69.47, 114.49, 115.54, 115.77, 119.60, 126.06, 126.09, 127.10, 127.38, 128.98, 130.78, 130.88, 133.63, 134.13, 139.55, 145.37, 160.51, 163.03 ppm.

3-Benzyl-2,3-dihydro-2-(3-nitrophenyl)quinazolin-4(1H)-one (11, C₂₁H₁₇N₃O₃)

¹H NMR (CDCl₃): δ = 3.86 (d, J = 15.6 Hz, 1H, CH₂), 5.57 (d, J = 15.6 Hz, 1H, CH₂), 5.76 (s, 1H, CH), 6.60 (d, J = 8.0 Hz, 1H, Ar-H), 6.92–6.96 (m, 1H, Ar-H), 7.23–7.27 (m, 2H, Ar-H), 7.28–7.35 (m, 4H, Ar-H), 7.48–7.52 (m, 1H, Ar-H), 7.67 (d, J = 8.0 Hz, 1H, Ar-H), 8.05–8.18 (m, 3H, Ar-H) ppm; ¹³C NMR (CDCl₃): δ = 47.52, 70.09, 114.88, 115.81, 119.86, 121.83, 124.02, 127.77, 127.92, 128.81, 128.84, 130.04, 132.23, 134.04, 136.21, 141.74, 144.50, 148.36, 163.09 ppm.

3-Benzyl-2,3-dihydro-2-(2-nitrophenyl)quinazolin-4(1H)-one (12, C₂₁H₁₇N₃O₃)

¹H NMR (CDCl₃): δ = 3.72 (d, J = 15.2 Hz, 1H, CH₂), 5.32 (br, 1H, NH), 5.61 (d, J = 15.2 Hz, 1H, CH₂), 6.21

(s, 1H, CH), 6.51 (d, J = 8.0 Hz, 1H, Ar-H), 6.86–6.89 (m, 1H, Ar-H), 7.25–7.32 (m, 6H, Ar-H), 7.55–7.56 (m, 2H, Ar-H), 7.58–7.60 (m, 1H, Ar-H), 8.04–8.07 (m, 2H, Ar-H) ppm; ¹³C NMR (CDCl₃): δ = 48.06, 66.25, 114.76, 114.98, 119.31, 125.93, 127.91, 127.95, 128.06, 128.68, 128.86, 129.81, 134.06, 134.37, 134.77, 135.79, 143.96, 147.78, 163.73 ppm.

3-Benzyl-2-(2-chlorophenyl)-2,3-dihydroquinazolin-4(1H)-one (13, C₂₁H₁₇ClN₂O)

¹H NMR (CDCl₃): δ = 3.69 (d, J = 15.2 Hz, 1H, CH₂), 4.98 (br, 1H, NH), 5.72 (d, J = 15.2 Hz, 1H, CH₂), 6.03 (s, 1H, CH), 6.51 (d, J = 8.0 Hz, 1H, Ar-H), 6.85–6.89 (m, 1H, Ar-H), 7.21–7.41 (m, 10H, Ar-H), 8.04 (dd, J = 1.2 Hz, J = 7.8 Hz, 1H, Ar-H) ppm; ¹³C NMR (CDCl₃): δ = 47.64, 67.27, 114.63, 115.61, 119.30, 127.34, 127.42, 127.70, 128.08, 128.69, 128.76, 130.13, 130.32, 132.11, 133.76, 136.07, 136.50, 144.54, 163.65 ppm.

3-Benzyl-2-(2,3-dichlorophenyl)-2,3-dihydroquinazolin-4(1H)-one (14, C₂₁H₁₆Cl₂N₂O)

¹H NMR (CDCl₃): δ = 3.67 (d, J = 15.2 Hz, 1H, CH₂), 5.03 (br, 1H, NH), 5.72 (d, J = 15.2 Hz, 1H, CH₂), 6.03 (s, 1H, CH), 6.51 (d, J = 8.0 Hz, 1H, Ar-H), 6.85–6.89 (m, 1H, Ar-H), 7.13–7.46 (m, 9H, Ar-H), 8.03–8.05 (m, 1H, Ar-H) ppm; ¹³C NMR (CDCl₃): δ = 47.71, 67.64, 114.74, 115.47, 119.46, 125.43, 127.83, 127.84, 128.12, 128.70, 128.82, 130.28, 130.83, 133.90, 134.12, 136.26, 138.47, 144.27, 163.50 ppm.

3-Benzyl-2-(2-chloro-6-fluorophenyl)-2,3-dihydroquinazolin-4(1H)-one (15, C₂₁H₁₆ClF₂N₂O)

¹H NMR (CDCl₃): δ = 3.84 (d, J = 15.2 Hz, 1H, CH₂), 4.43 (br, 1H, NH), 5.50 (d, J = 15.2 Hz, 1H, CH₂), 6.40 (s, 1H, CH), 6.85–6.89 (m, 1H, Ar-H), 6.91–6.96 (m, 1H, Ar-H), 7.20–7.29 (m, 9H, Ar-H), 8.05 (dd, J = 1.6 Hz, J = 1.6 Hz, 1H, Ar-H) ppm; ¹³C NMR (CDCl₃): δ = 47.13, 66.39, 113.74, 115.79, 116.03, 119.01, 126.08, 126.12, 127.58, 128.24, 128.56, 128.61, 130.59, 130.69, 133.36, 136.46, 144.71, 160.65, 163.05, 163.08, 163.17 ppm.

3-(2-Chlorobenzyl)-2,3-dihydro-2-phenylquinazolin-4(1H)-one (**16**, C₂₁H₁₇ClN₂O)

¹H NMR (CDCl₃): δ = 4.11 (d, *J* = 16.0 Hz, 1H, CH₂), 5.45 (d, *J* = 16.0 Hz, 1H, CH₂), 5.72 (s, 1H, CH), 6.57 (d, *J* = 8.0 Hz, 1H, Ar-H), 6.89–6.93 (m, 1H, Ar-H), 7.20–7.29 (m, 2H, Ar-H), 7.30–7.59 (m, 8H, Ar-H), 8.05 (dd, *J* = 1.6 Hz, *J* = 1.2 Hz, 1H, Ar-H) ppm; ¹³C NMR (CDCl₃): δ = 44.93, 71.78, 114.51, 115.74, 119.32, 126.42, 127.11, 128.58, 128.76, 129.00, 129.15, 129.35, 129.48, 133.43, 133.77, 134.31, 139.25, 145.25, 163.40 ppm.

3-(2-Chlorobenzyl)-2,3-dihydro-2-(3-nitrophenyl)-quinazolin-4(1H)-one (**17**, C₂₁H₁₆ClN₃O₃)

¹H NMR (CDCl₃): δ = 4.27 (d, *J* = 16.0 Hz, 1H, CH₂), 5.41 (d, *J* = 16.0 Hz, 1H, CH₂), 5.85 (s, 1H, CH), 6.62 (d, 1H, *J* = 8.0 Hz, Ar-H), 6.93–6.95 (m, 1H, Ar-H), 7.22–7.35 (m, 4H, Ar-H), 7.48–7.52 (m, 2H, Ar-H), 7.67–7.69 (m, 1H, Ar-H), 8.05–8.07 (m, 1H, Ar-H), 8.15–8.20 (m, 2H, Ar-H) ppm; ¹³C NMR (CDCl₃): δ = 45.13, 70.73, 114.98, 116.03, 120.14, 121.78, 124.10, 127.33, 128.92, 128.99, 129.56, 129.67, 130.06, 132.11, 133.43, 133.87, 134.10, 141.51, 144.37, 148.39, 163.13 ppm.

3-(2-Chlorobenzyl)-2,3-dihydro-2-(4-nitrophenyl)-quinazolin-4(1H)-one (**18**, C₂₁H₁₆ClN₃O₃)

¹H NMR (CDCl₃): δ = 4.19 (d, *J* = 16.0 Hz, 1H, CH₂), 5.49 (d, *J* = 16.0 Hz, 1H, CH₂), 5.81 (s, 1H, CH), 6.60 (d, *J* = 8.0 Hz, 1H, Ar-H), 6.93–6.96 (m, 1H, Ar-H), 6.97–7.28 (m, 2H, Ar-H), 7.29–7.36 (m, 2H, Ar-H), 7.48–7.52 (m, 3H, Ar-H), 8.05 (dd, *J* = 1.2 Hz, *J* = 1.6 Hz, 1H, Ar-H), 8.17 (d, *J* = 8.0 Hz, 2H, Ar-H) ppm; ¹³C NMR (CDCl₃): δ = 45.18, 70.51, 114.98, 116.02, 120.17, 124.22, 127.24, 127.35, 128.88, 129.09, 129.62, 129.69, 133.55, 133.83, 134.13, 144.20, 146.29, 148.32, 163.00 ppm.

3-(2-Chlorobenzyl)-2-(2-chlorophenyl)-2,3-dihydroquinazolin-4(1H)-one (**19**, C₂₁H₁₆Cl₂N₂O)

¹H NMR (CDCl₃): δ = 4.03 (d, *J* = 16.0 Hz, 1H, CH₂), 5.61 (d, *J* = 16.0 Hz, 1H, CH₂), 6.08 (s, 1H, CH), 6.54 (d, *J* = 8.0 Hz, 1H, Ar-H), 6.85–6.87 (m, 1H, Ar-H), 7.21–7.29 (m, 4H, Ar-H), 7.30–7.44 (m, 4H, Ar-H), 7.57 (dd, *J* = 2.0 Hz, *J* = 1.6 Hz, 1H, Ar-H), 8.03 (dd, *J* = 1.6 Hz, *J* = 1.2 Hz, 1H, Ar-H) ppm; ¹³C NMR (CDCl₃): δ = 45.60, 68.03, 114.73, 115.62, 119.40, 127.22, 127.29, 127.38, 128.68, 128.89, 129.40, 129.57, 130.16, 130.37, 132.12, 133.65, 133.86, 134.06, 135.92, 144.65, 163.83 ppm.

3-(2-Chlorobenzyl)-2-(2,6-dichlorophenyl)-2,3-dihydroquinazolin-4(1H)-one (**20**, C₂₁H₁₅Cl₃N₂O)

¹H NMR (CDCl₃): δ = 4.05 (d, *J* = 16.0 Hz, 1H, CH₂), 4.46 (br, 1H, NH), 5.50 (d, *J* = 16.0 Hz, 1H, CH₂), 6.56 (d,

J = 8.0 Hz, 1H, CH), 6.79 (s, 1H, Ar-H), 6.79–6.89 (m, 1H, Ar-H), 7.13–7.43 (m, 8H, Ar-H), 8.04 (dd, *J* = 1.6 Hz, *J* = 1.2 Hz, 1H, Ar-H) ppm; ¹³C NMR (CDCl₃): δ = 43.68, 68.61, 113.56, 114.20, 118.58, 127.04, 128.49, 128.77, 129.55, 129.44, 130.62, 132.07, 133.30, 133.58, 133.79, 133.89, 136.12, 145.61, 163.51 ppm.

3-(2-Chlorobenzyl)-2-(2,4-dichlorophenyl)-2,3-dihydroquinazolin-4(1H)-one (**21**, C₂₁H₁₅Cl₃N₂O)

¹H NMR (CDCl₃): δ = 4.05 (d, *J* = 16.0 Hz, 1H, CH₂), 5.01 (br, 1H, NH), 5.57 (d, *J* = 16.0 Hz, 1H, CH₂), 6.04 (s, 1H, CH), 6.54 (d, *J* = 8.0 Hz, 1H, Ar-H), 6.87–6.91 (m, 1H, Ar-H), 7.16–7.44 (m, 7H, Ar-H), 7.56 (dd, *J* = 2.0 Hz, *J* = 7.8 Hz, 1H, Ar-H), 8.02 (dd, *J* = 1.6 Hz, *J* = 8.0 Hz, 1H, Ar-H) ppm; ¹³C NMR (CDCl₃): δ = 45.52, 67.63, 114.80, 115.56, 119.83, 127.33, 127.60, 128.07, 128.71, 129.02, 129.39, 129.59, 130.23, 132.78, 133.70, 133.88, 134.01, 134.65, 135.40, 144.38, 163.65 ppm.

3-(2-Chlorobenzyl)-2-(2-chloro-6-fluorophenyl)-2,3-dihydroquinazolin-4(1H)-one (**22**, C₂₁H₁₅Cl₂FN₂O)

¹H NMR (CDCl₃): δ = 4.17 (d, *J* = 16.0 Hz, 1H, CH₂), 4.72 (br, 1H, NH), 5.49 (d, *J* = 16.0 Hz, 1H, CH₂), 6.40 (s, 1H, CH), 6.56 (d, *J* = 8.0 Hz, 1H, Ar-H), 6.87–6.98 (m, 2H, Ar-H), 7.19–7.29 (m, 4H, Ar-H), 7.30–7.49 (m, 3H, Ar-H), 8.06 (dd, *J* = 1.6 Hz, *J* = 1.2 Hz, 1H, Ar-H) ppm; ¹³C NMR (CDCl₃): δ = 44.64, 66.98, 113.99, 115.89, 116.13, 119.28, 126.21, 126.24, 127.16, 128.67, 128.72, 129.43, 129.51, 130.64, 130.74, 133.44, 133.66, 133.85, 144.77, 160.45, 162.97, 163.39 ppm.

References

1. Tour BB, Hall DG (2009) Chem Rev 109:4439
2. Domling A, Ugi I (2000) Angew Chem Int Ed 39:3168
3. Zhu J, Bienayme H (2005) Multicomponent reactions. Wiley-VCH, Weinheim
4. Hour M, Huang L, Kuo S, Xia Y, Bastow K, Nakanishi Y, Hamel E, Lee K (2000) J Med Chem 43:4479
5. Na YH, Hong SH, Lee JH, Park WK, Baek DJ, Koh HY, Cho YS, Choo H, Pae AN (2008) Bioorg Med Chem 16:2570
6. Abdel-Jalil RJ, Volter W, Saeed M (2004) Tetrahedron Lett 45:3475
7. Matsuno K, Ichimura M, Nakajima T, Tahara K, Fujiwara S, Kase H, Vishiki J, Giese NA, Pandey A, Scarborough RM, Lokker NA, Yu J-C, Irie J, Tsukuda E, Ide S-I, Oda S, Nomoto Y (2002) J Med Chem 45:3057
8. Khurana JM, Kukreja G (2003) J Heterocycl Chem 40:677
9. Su W, Yang B (2002) Aust J Chem 55:695
10. Shi D, Rong L, Wang J, Zhuang Q, Wang X, Hu H (2003) Tetrahedron Lett 44:3199
11. Dabiri M, Salehi P, Otokesh S, Baghbanzadeh M, Kozehgarya G, Mohammadi AA (2005) Tetrahedron Lett 46:6123
12. Salehi P, Dabiri M, Baghbanzadeh M, Bahramnejad M (2006) Synth Commun 36:2287

13. Chen JX, Wu D, He F, Liu MC, Wu H, Ding JC, Su WK (2008) *Tetrahedron Lett* 49:3814
14. Dabiri M, Salehi P, Baghbanzadeh M, Zolfigol MA, Agheb M, Heydari S (2008) *Catal Commun* 9:785
15. Shaterian HR, Oveisi AR, Honarmand M (2010) *Synth Commun* 40:1231
16. Wang L-M, Hu L, Shao J-H, Yu T, Zhang L (2008) *J Fluorine Chem* 129:1139
17. Dabiri M, Salehi P, Baghbanzadeh M (2007) *Monatsh Chem* 138:1191
18. Saffar-Teluri A, Bolouk S (2010) *Monatsh Chem* 141:1113
19. El-Sabbagh OI, Ibrahim SM, Baraka MM, Kothayer H (2010) *Arch Pharm* 343:274
20. Zhang ZH, Lu HY, Yang SH, Gao JW (2010) *J Comb Chem* 12:643
21. Rostamizadeh S, Amani AM, Mahdavinia GH, Sepehrian H, Ebrahimi S (2010) *Synthesis* (8):1356
22. Rao VB, Hanumanth P, Ratnam CV (1979) *Indian J Chem* 18B:493
23. Karimi-Jaberi Z, Keshavarzi M (2010) *Chin Chem Lett* 21:547
24. Karimi-Jaberi Z, Amiri M (2010) *Heteroat Chem* 21:96
25. Karimi-Jaberi Z, Amiri M, Sadeghi N (2010) *Synth Commun* 40:2948